Key Takeaways:
Merck (NYSE: MRK) received European Commission approval for its blockbuster drug Keytruda to treat a specific form of platinum-resistant ovarian carcinoma in adults, the company announced on April 2, 2026.
"This approval marks a significant milestone for women with platinum-resistant recurrent ovarian carcinoma in the European Union," said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories.
The approval covers the use of Keytruda (pembrolizumab) combined with paclitaxel, with or without bevacizumab. It is for adult patients whose tumors express PD-L1 with a Combined Positive Score (CPS) of 1 or greater and who have received one or two prior systemic treatment regimens.
This label expansion in the EU is expected to be a positive driver for Merck's revenue, further solidifying Keytruda's position as a leading cancer therapy. The approval strengthens the company's oncology portfolio and could boost investor confidence as it opens a new treatment option for a difficult-to-treat cancer.
The approval provides a new therapeutic option for a patient population with limited choices. Investors will watch for Merck's next earnings report to quantify the initial sales impact from this new indication in the EU.
This article is for informational purposes only and does not constitute investment advice.
